Takeda’s 60 million Euro investment into state-of-the-art facility brings 40 new jobs and industry leading innovation to Irish shores.
Bringing the international to the local is key to spreading innovative technology. This is why on July 5, 2019, Takeda President and CEO Christophe Weber, Regina Doherty, IrishMinister for Employment Affairs and Social Protection, the Japanese Ambassador to Ireland, Mari Miyoshi together with Thomas Wozniewski,
Global Manufacturing & Supply Officer, and Milano Furuta, Corporate Strategy Officer & Chief of Staff, participated in the grand opening ceremony of P2, a standalone, high containment, cutting-edge production facility dedicated to the manufacture of Takeda’s treatment for multiple myeloma.
Increasing Takeda’s manufacturing footprint in Ireland
Takeda has enjoyed a prosperous relationship with Ireland over the last twenty years. As an attractive location for investment and development, Ireland has always been a powerful magnet for the pharmaceutical industry. It is known globally for its diverse and highly skilled workforce, alongside its strong reputation for clinical and academic excellence in R&D. Takeda understands the importance of putting people at the centre of innovation, and the 40 new jobs that this ground-breaking facility is creating will offer the best and brightest Irish graduates in STEM subjects the opportunity to grow and flourish with Takeda Ireland Grange Castle.
The Takeda Grange Castle facility site as an epicentre of innovation
Located at the high technology Pharmaceutical and Biotechnology Business Park in Dublin, Grange Castle is a launch vehicle for new strategic products aimed at global markets. The P2 plant’s innovative design as an ‘all-in-one’ facility incorporates the entire production process from active pharmaceutical ingredients to drug product and packaging under one roof. This significantly increases the agility, flexibility and robustness of the supply chain to ensure unconstrained availability of crucial medicines to patients worldwide.
In addition to the use of state-of-the-art containment to fully ensure the safety of employees, the design team has implemented best-in-class digital technologies to guarantee the facility utilizes the latest developments in paper-less automation, robotics and augmented reality. Furthermore, real-time access to data and big data analytics will safeguard the quality and reliability of all process steps and will be a foundation for continuous improvement.
Positioning Grange Castle and Takeda as pioneers in the European market place
During the grand opening ceremony, Takeda also announced a further 30 million Euro investment into Grange Castle with the planned construction of P3, a state-of-the-art facility for commercial scale cell therapy production and the first of its type in Ireland. The P2 and P3 plants demonstrate Takeda’s core commitment to facilitate innovation by investing in the technology and people required to stand at the forefront of the pharmaceutical industry.